REVIEW

Autoimmunity and pulmonary hypertension: a perspective

M.R. Nicolls, L. Taraseviciene-Stewart, P.R. Rai, D.B. Badesch and N.F. Voelkel

ABSTRACT: The association between autoimmunity and pulmonary arterial hypertension (PAH) has been appreciated for >40 yrs, but how autoimmune injury might contribute to the pathogenesis of this disease has only been examined in a case-specific manner.

It is becoming increasingly clear that a variety of diverse clinical diseases, ranging from viral infections to connective tissue disorders, can culminate in pulmonary vascular pathology that is indistinguishable. Is there a hitherto unappreciated biology that unites these seemingly unrelated conditions?

The answer to this question may come from the increasing body of evidence concerned with the central importance of regulatory T-cells in preventing inappropriate B-cell activity. Two striking similarities between conditions associated with severe angioproliferative pulmonary hypertension are a defect in the CD4 T-cell compartment and auto-antibody production. Pathogenic auto-antibodies targeting endothelial cells are capable of inducing vascular endothelial apoptosis and may initiate the development of PAH.

The present review will focus on what is known about autoimmune phenomena in pulmonary arterial hypertension patients, in order to better consider whether an early loss of self-tolerance followed by autoimmune injury could influence the early development of severe angioproliferative pulmonary hypertension.

KEYWORDS: Auto-antibodies, autoimmunity, endothelium, immune regulation, immune tolerance, pulmonary hypertension

Severe pulmonary arterial hypertension (PAH) can be a manifestation of a number of collagen vascular diseases and viral infections. For example, ~12% of patients with scleroderma will develop PAH [1]. Other disorders, such as systemic lupus erythematos, polymyositis, Sjögren’s syndrome and Hashimoto’s thyroiditis have all been associated with the development of severe PAH [2]. It is also known that certain viral infections, e.g. HIV and human herpes virus (HHV)-8, can be associated with the development of severe PAH [3-6]. Of great interest, is that all of these conditions are either characterised by, or have a propensity to, autoimmunity. A self-directed immune attack may occur because of a relative paucity of regulatory CD4 cells. It is already known that for some of these diseases, there is a diminution of the putative regulatory subset thought responsible for peripheral immune tolerance, the CD4+CD25+ cell. The present review will discuss how a loss of self-tolerance could initiate a process which ultimately results in PAH.

PULMONARY HYPERTENSION: PATHOLOGY AND CLASSIFICATION

The most recent clinical and pathological classifications of pulmonary hypertensive diseases were established at the Evian conference [7], and updated in 2003 in Venice, Italy [8]. Pathologically, PAH is characterised by a proliferation of endothelial cells and expansion of vascular smooth muscle and adventitial cells in pulmonary arteries [9]. There is a growing appreciation that vasoconstriction of pulmonary pre-capillary arterioles may not be the single most important factor leading to severe pulmonary vascular remodelling. Although not yet widely accepted, the authors of the current review use the term “severe angioproliferative pulmonary hypertension” (SAPPH) [10] to distinguish, categorically, between pulmonary vascular disease which develops because of endothelial cell proliferation and pulmonary vascular disease which develops
predominantly because of increased muscularisation of vessel walls [8]. Examples of PAH arising from endothelial cell pathology include idiopathic pulmonary arterial hypertension (IPAH; formerly known as primary pulmonary hypertension) [8], HIV-induced PAH and CREST (calcinosis, Raynaud’s phenomenon, oesophageal dysfunction, sclerodactyly, telangiectasia)-related SAPPH. Examples of PAH associated with severe muscularisation of the pre-capillary arterioles, which demonstrate no clear cut evidence for endothelial cell pathology, include some hypoxia-associated PAH conditions such as chronic mountain sickness [11, 12] and neonatal PAH [13, 14]. The term SAPPH is preferred for several reasons. 1) SAPPH provides a pathobiological concept, (i.e. angiogenesis or angioproliferation). 2) SAPPH unites both so-called primary and secondary forms of PAH, under the banner of “severe” and associates the condition with complex pulmonary vascular lesions, including plexiform lesions. 3) SAPPH likely provides prognostic and therapeutic information in that, at the present time, the treatment for these severe forms of angioproliferative PAH is quite similar [10]. SAPPH is also characterised by the presence of inflammatory cells in and around affected pulmonary vessels. Heath [15] described the presence of mast cells in plexiform lesions in patients with primary PAH 30 yrs ago. Further work by Tuder et al. [16], and also Humbert et al. [17] described the presence of inflammatory infiltrates in the vascular lesions of PAH. Figures 1 and 2 illustrate the immune pathology in a patient with IPAH which is notable for lymphocyte and mast cell infiltration, as well as immunoglobulin G deposition in and around the narrowed and occluded vascular lumen.

PAH: AUTOIMMUNITY AND IMMUNOREGULATION

Whether the presence of inflammatory and immune cells, such as T- and B- lymphocytes in the lesions [16] is cause or consequence of SAPPH remains unknown and may be debated for some time. However, it has been recognised for >40 yrs that there are associations between autoimmune disorders and severe PAH. Little progress has been made in the current

![Image]

**FIGURE 1.** Immune pathology of pulmonary arteriole from an idiopathic pulmonary arterial hypertension patient. A 38-yr-old (antinuclear antibody positive, human herpes virus 8 positive) female expired with idiopathic pulmonary arterial hypertension. a) Haematoxylin and eosin stain showing affected arteriole surrounded by palisading mononuclear cells. b) CD4⁺ (fast red substrate (red staining); white arrow) and CD8⁺ (3,3’-diaminobenzidine (brown staining); black arrow) cells around lesion. c) Giemsa stain of mast cells indicating peri-arteriole infiltration. d) A magnified view of the lesion, mast cells are indicated by the black arrows.
understanding of how immune injury may be involved in the pathogenesis of SAPPH. In addition to the well recognised association between autoimmunity and SAPPH, there is also a link between immune insufficiency and SAPPH, because HIV+ patients and patients with AIDS develop PAH and vascular lesions which are histologically indistinguishable from IPAH. The recent description of latent HHV-8 [18] in patients with IPAH further begs the question of how the immune system modulates the development of PAH.

The answer to this question may be that most conditions associated with SAPPH are associated with a defect in the CD4 T-cell compartment, meaning that these conditions are either characterised by an absolute deficiency of CD4 cells, a decreased CD4/CD8 ratio and/or a diminished relative percentage of CD4+CD25+ cells, the putative regulatory T-cell (Treg) subset. Specifically, HIV [3], HHV-8 [4, 5] and the hepatitis C virus [6, 19–21] are all infections associated with a CD4 defect, autoimmune phenomena (including auto-antibodies) and the development of SAPPH. Similarly, other PAH-associated conditions, including connective tissue disorders, are also associated with a CD4 cell defect. For example, scleroderma [22, 23], systemic lupus erythematosus [24, 25], polymyositis [26], Hashimoto’s thyroiditis [27] and Sjögren’s Syndrome [28] can all exhibit selective CD4 cell defects and autoimmunity (again including auto-antibodies). More specifically, scleroderma and lupus are associated with a reduction in peripheral CD4+CD25+ cells, the putative Treg population [23–25]. Furthermore, PAH has been described following splenectomy [29]. Finally, it was recently reported that a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, which is caused by a mutation leading to the loss of function of the autoimmune regulator (AIRE) protein, died with fatal IPAH [30]. The AIRE gene is of central importance in the development of thymus-dependent self-tolerance. T-cell, B-cell, macrophage and mast cell infiltration is a characteristic pathological feature of plexiform lesions from SAPH patients [16, 31]. Furthermore, it is estimated that 30–40% of the patients with IPAH are antinuclear antibody positive, and another 10–15% of those patients may express antiphospholipid antibodies [32, 33]. A unifying hypothesis that addresses these cumulative findings is that, in the setting of relative or absolute immunodeficiency (which includes diminished Treg activity), immune dysregulation occurs and leads to the activation of pathogenic autoreactive B-cells and T-cells.

If autoimmunity triggers the development of SAPPH, then why is the prevalence of PAH relatively low for certain autoimmune conditions such as systemic lupus erythematosus (6.2%) [34]? If the autoimmune phenomena resulting in end-organ damage are at play, why is the pulmonary vasculature not universally involved in these autoimmune connective tissue disorders? While this question can’t be answered definitively at this time, there are several possibilities. It is known that in certain autoimmune conditions, a genotype can confer significantly elevated risk without complete disease penetrance. For example, in type 1 diabetes while increased risk is conferred on the basis of the HLA-DR-DQ genotype, fewer than 10% of susceptible individuals or 30–40% of identical twins of a patient with type 1 diabetes will develop the disease [35]. Environmental factors such as dietary or viral infections have been invoked as necessary “second hits” to develop this disease. Similarly, it is likely that a two-hit phenomenon may be required such that autoimmunity results in vascular injury and PAH. The current authors hypothesise, that a common factor in PAH-associated conditions is a loss of immunoregulation and that the second “permissive” factor could be the patient’s genotype and/or concomitant vascular injury due to infection or temporary high shear stress. In summary, incomplete penetrance of PAH in autoimmune conditions associated with PAH may be due to the requirement of two or more additional factors that are present in a minority of the patients.

SCLERODERMA: A PARADIGM OF AUTOIMMUNE PAH

Scleroderma is a connective tissue disorder characterised by excessive collagen accumulation in the skin and visceral organs. As mentioned above, it is estimated that ~12% of scleroderma patients will develop SAPH [1]. Scleroderma researchers believe that endothelial cell apoptosis may be the first event in the pathogenesis of scleroderma [36]. Anti-endothelial antibodies are found in the circulation of scleroderma patients [37, 38], and their presence correlates with the clinical
progression of this disease [38]. An instigating injury to endothelial cells in scleroderma that may trigger such auto-antibody formation may be viral infection [39]. A number of investigators have found evidence for viral infections, such as Epstein-Barr virus, parvovirus B19 and hepatitis C, E, and G in patients with scleroderma [40–45]. Although the role of cytomegalovirus (CMV) in the pathogenesis of scleroderma is debated [46], indirect evidence for a role of CMV-specific antibodies in the development of this disease has also been discussed [47, 48]. Not only are absolute lymphocyte counts reduced in scleroderma [49, 50], but scleroderma patients also have relatively fewer CD4+CD25+ cells in the peripheral circulation compared with healthy controls [23]. In this setting of diminished Tregs, a dysregulation of B-cells is also observed [51]. Plexiform lesions found in the arterial walls of scleroderma PAH patients include an inflammatory infiltrate [52] consisting of macrophages, T-cells, B-cells and mast cells [53–55]. In summary, scleroderma is an autoimmune disorder that has been associated with viral infection, endothelial damage, diminished Tregs, dysregulated B-cells, abundant mast cells and auto-antibodies. This review will subsequently discuss how Treg activity is related to B-cell activity, how mast cell infiltration is linked to the production of auto-antibodies, and finally, how these processes may culminate in PAH.

AUTOREACTIVE B-CELL ACTIVATION IN THE ABSENCE OF T-CELL REGULATION

Two findings, made nearly 30 yrs ago, strongly implicated T-cells as being responsible for the control of self-reactive T-cells and B-cells in the maintenance of self-tolerance. In 1969 Nishizuka and Sakakura [56] demonstrated that neonatal thymectomy of normal mice, most notably between day 2 and 4 after birth, led to autoimmune destruction of ovaries. In 1973, Penhale et al. [57] showed that thymectomy of adult rats followed by several exposures to sublethal X-irradiation led to the development of autoimmune thyroiditis. As inoculation of normal CD4+ cells prevented these diseases, both groups suspected that depletion of suppressor T-cells was a putative mechanism for the development of autoimmunity [58, 59]. As this population was eventually narrowed down to the CD4+CD25+ cell, it became clear that depletion of this relatively small subpopulation (5–10% of CD4+ cells) was sufficient to break natural self-tolerance and incite chronic and destructive autoimmune diseases. This loss of self-tolerance was associated with the appearance of various disease-specific auto-antibodies [60]. With complete elimination of CD4+CD25+ cells, systemic autoimmunity occurs as manifested by multi-organ inflammation and auto-antibody production [61].

In addition to controlling T-cell activity, Tregs influence B-cell responses. For example, CD4+CD25+ Tregs have been shown to directly inhibit lipopolysaccharide-induced proliferation of B-cells in vitro. In an adoptive transfer system, CD4+CD25+ T-cells downregulate T-cell-mediated production of self-reactive antibodies. As activated B-lymphocytes produce CCL5 and attract CD4+CD25+ T-cells in vitro, it has been postulated that B-cell recruitment of CD4+CD25+ T-cells could limit B-cell autoimmune responses [62]. CD4+CD25+ cells prevent the activation of anti-DNA antibodies in a transgenic system [63].

Thus, Tregs regulate antibody responses against self and nonself antigens. Tregs may exert a direct inhibitory effect on B-cells [62] or may inhibit T-cell differentiation [64]. Therefore, in the absence of appropriate regulation by T-cells, auto-antibodies can arise, and autoimmune disease can develop. Thus, a loss of Treg-mediated self-tolerance leads, not only to a loss in T-cell tolerance, but to a breakdown in B-cell tolerance as well. In the absence of these Tregs, other cells presumably provide stimulatory signals to relevant self-reactive B-cells, rescue them from apoptosis, and stimulate them to form pathogenic antibodies [65].

A conventional understanding of autoimmune disorders implicates an inappropriately vigorous T-cell compartment in autoimmune disorders such as diabetes and multiple sclerosis [66]. Conversely, autoimmune diseases such as Sjögren’s disease and systemic lupus erythematosus, are distinguished by pathogenic auto-antibody production in the setting of apparently compromised Treg function. Autoimmunity in PAH may more closely resemble the latter group of diseases. As discussed above, Treg activity is normally responsible for preventing auto-antibody production. Antibodies directed against the vascular endothelium could certainly promote endothelial apoptosis. It is possible that endothelial apoptosis, secondary to autoimmune injury, could initiate dysfunctional endothelial cell proliferation that culminates in PAH in the same manner that endothelial apoptosis, induced by vascular endothelial growth factor antagonism, results in endothelial cell proliferation and PAH [67]. Anti-endothelial antibodies are present in autoimmune disorders associated with PAH including systemic lupus erythematosus [68], mixed connective tissue disease [69] and scleroderma [38]. In lupus and Sjögren’s syndrome, antibody and complement deposits are localised in the walls of pulmonary arteries of patients with PAH [70, 71]. So, in short, the effector cells in this form of autoimmunity may be B-cells which (following differentiation into plasma cells) produce anti-endothelial antibodies. Although the role of autoreactive B-cells is emphasised here, the presence of T-cells in the inflammatory lesion suggests that dysregulated T-cells also contribute to autoimmune injury in PAH.

It is helpful to consider the antiphospholipid syndrome which may be a clinical scenario that has many elements of the PAH model described above. Patients with the antiphospholipid syndrome have altered T-lymphocyte subsets in the periphery, most notably a significantly reduced CD4+CD25+ population [72]. The antiphospholipid syndrome is often associated with viral syndromes associated with PAH, such as HIV and hepatitis C, which can have immunomodulatory effects [73]. The hypothesis posited here states that detects in the Treg population (which could occur after a viral infection) will lead to a loss of Treg activity with subsequent production of auto-antibodies and associated vascular endothelial injury. The antiphospholipid syndrome is associated with antiphospholipid antibodies that bind and activate endothelial cells. This antibody engagement ultimately leads to apoptosis of vascular endothelial cells [74, 75]. Finally, unmanipulated athymic nude mice, that also have an isolated deficiency of T-cells, have been demonstrated to spontaneously develop antiphospholipid antibodies, whereas severe combined immunodeficiency mice, which lack both T- and B-cells, do not have antiphospholipid antibodies [76]. Thus, in the antiphospholipid syndrome and other autoimmune disorders, the effector cell of greatest
importance may be the dysregulated B-cell that produces auto-

antibodies to vascular endothelium because normal regulatory

T-cell activity is decreased or absent.

When Treg activity is diminished, mast cells, rather than T-
cells, may potentiate B-cell activation via interleukin (IL)-4 (i.e.

mast cells may substitute as a source for IL-4 to increase local

B-cell activation [77]). Of note, mast cells are a significant

source of non-T-cell IL-4 [78], and IL-4 has been implicated as

an expander of autoreactive B-cells [79] and a cytokine of

central importance in an experimental model of scleroderma

[80–82]. The presence of mast cells in and around plexiform

lesions has long been observed [15, 31]. Mast cells were

originally thought to be pathogenically important in PAH [83],

and were discounted as it was subsequently demonstrated

that a dearth of mast cells did not prevent experimental

PAH [84], while a surfeit of mast cells [85, 86] was not

associated with clinical PAH. However, mast cells are

indeed present in both the inflammatory lesions of PAH patients

[31] and monocrotaline-induced PAH in athymic nude rats

lacking T-cells [87]. The latter group is interesting because

monocrotaline-induced PAH is exacerbated by an absence of

Tregs (i.e. when no T-cells are present) and is notable for mast

cell infiltration in the inflammation around plexiform lesions.

The present authors propose that the presence of mast cells

may not be required for all subtypes of PAH, but that, as in

other autoimmune diseases, mast cells may be an important

link between the innate and adaptive immune responses [88,

89]. Rather than being absolutely required for the develop-

ment of PAH, mast cells may be important facilitators of the

immune response by potentiating autoreactive B-cells. Given

the putative importance of cytokines and chemokines in the

generation of an adaptive immune response, it is important to

to also note that IL-1 and IL-6 serum levels are markedly elevated

in severe PAH and may significantly contribute to the inflam-

matory milieu of this disease [90].

BONE MORPHOGENETIC PROTEIN RECEPTOR II: A NEW INTERPRETATION OF ITS ROLE IN THE DEVELOPMENT OF PAH

A genetic basis has recently been determined for some cases of

familial PAH, i.e. the involvement of germline mutations of

bone morphogenetic protein receptor II (BMPR2) [91]. BMPR2

is a member of the tumour growth factor (TGF)-β receptor

family and is a ligand for bone morphogenetic proteins (BMPs)

2, 4, 6 and 7, but not TGF-β [92]. Of pertinence to the current

model is that BMP2 and -4 have roles in the development, growth potential and apoptosis of T- and B-cells. BMP2 and

BMP4 (and likely its receptor, BMPR2) are also essential for

thymocyte differentiation [93–95], and proper Treg develop-

ment in the thymus is critical to avoid autoimmune disease

[60]. BMP2 mediates growth arrest and apoptosis of B lineage

cells [96, 97]. Finally, BMP4 is essential for the generation of B-

cell progenitors (in addition to erythroid-myeloid colony form-

ing cells and natural killer progenitors) [98]. It is conceivable

that as a receptor for these BMPs, BMPR2 is intimately

involved in these immune effects. This has already been

suggested for the BMP effects on thymic maturation [93]. Thus,

it is possible that BMPR2 mutations could deleteriously affect

the normal development, maturation, growth arrest and death

of lymphocytes. In a manner analogous to patients developing

PAH because of AIRE gene mutations [30], germline BMPR2

mutations may, in part, result in PAH because they lead to a

fundamental defect in peripheral immune tolerance (i.e.

inappropriate Treg development and/or abnormal ability to

delete B-cells). This idea opens interesting avenues of research

focusing on the role of BMPR2 in immune tolerance rather than

simply on its effects on smooth muscle cell growth.

AN INTEGRATED MODEL OF SAPPH DEVELOPMENT

The fact that PAH generally does not respond to immunosup-

pression may explain why investigators have not comprehen-

sively explored a causal link between autoimmune injury and

PAH. However, it is quite possible that a maladaptive response to

an initial inflammatory injury results in a delayed tissue

injury response that has a biology entirely distinct from the

triggering immune insult and is no longer responsive to

immunotherapy, which may have been responsive in the

“initiation phase”. In the case of PAH, endothelial cell

destruction by immune-mediated injury may result in the

generation of apoptosis-resistant endothelial cells which

share features with malignant cells [99–101]. In this scenario,

the “law of the monolayer” is broken, and these endothelial

cells proliferate, become “heaped up” and eventually

obscure the vessel lumen [16]. These ideas are represented in

figure 3.

CONCLUSION

National Institutes of Health registry data indicated that the

median survival of patients with sporadic PAH was 2.8 yrs,

with survival rates at 1, 3, and 5 yrs being 68, 48 and 34%,

respectively [102]. While prostanoid therapy is improving

survival for certain forms of PAH [103], PAH remains a

frequently lethal disease of relatively mysterious origins. For

>40 yrs it has been recognised that autoimmune phenomena

are associated with PAH, but it has never been previously

demonstrated that autoimmune, itself, may be a root cause

for certain forms of PAH. The human and financial toll of PAH

is significant. For example, the prevalence of scleroderma in

the USA was ~9,000 patients in 1996 [104], and, as noted, 12%

of scleroderma patients will develop PAH [105–108]. The 1997

USA cost of caring for scleroderma patients was $1.5 billion/

year with the majority of money going towards the treatment

of PAH [109]. Current treatment strategies for subtypes of

PAH known to be associated with autoimmune disorders are

currently no different than management of PAH without an

established autoimmune association [110]. If autoimmunity is

truly important in the pathogenesis of PAH, then at risk

patients (such as those with scleroderma or PAH family

members with BMPR2 mutations) can potentially be targeted

with immunotherapy designed to prevent the establishment

and propagation of autoimmune injury. Developing an under-

standing of how autoimmunity can trigger PAH would be

fundamental to the ongoing discussion of how autoimmunity

may contribute to PAH [111, 112].

The present authors propose that the presence of mast cells

may not be required for all subtypes of PAH, but that, as in

other autoimmune diseases, mast cells may be an important
with the disease, but have not previously been pathogenetically integrated.

In summary, by identifying a critical immune basis for many forms of pulmonary arterial hypertension, a rational design of therapeutic targets for this group of frequently fatal diseases will be strongly facilitated.

REFERENCES

1 Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. *Ann Rheum Dis* 2003; 62: 1088–1093.

2 Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. *Prog Cardiovasc Dis* 2002; 45: 225–234.

3 Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. *Autoimmun Rev* 2002; 1: 329–337.

4 Parravinci C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV VL-6, in HIV-seronegative Castleman’s disease. *Am J Pathol* 1997; 151: 1517–1522.

5 Kemeny L, Kiss M, Gyulai R, et al. Human herpesvirus 8 in classic Kaposi sarcoma. *Acta Microbiol Immunol Hung* 1996; 43: 391–395.

6 Onji M, Doi Y, Miyaoka H, Masumoto T, Horiike N, Ohta Y. Serum levels of soluble CD4 and CD8 in patients with chronic viral hepatitis. *Hepatogastroenterology* 1994; 41: 377–379.

7 Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2004; 43: Suppl. 12, 55–125.

8 Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23–25, 2003. *J Am Coll Cardiol* 2004; 43: Suppl. 12, 1S–90S.

9 Veeraraghavan S, Koss MN, Sharma OP. Pulmonary veno-occlusive disease. *Curr Opin Pulm Med* 1999; 5: 310–313.

10 Voelkel NF, Cool C. Pathology of pulmonary hypertension. *Cardiol Clin* 2004; 22: 343–351.

11 Tucker A, Rhodes J. Role of vascular smooth muscle in the development of high altitude pulmonary hypertension: an interspecies evaluation. *High Alt Med Biol* 2001; 2: 173–189.

12 Anand IS, Wu T. Syndromes of subacute mountain sickness. *High Alt Med Biol* 2004; 5: 156–170.

13 Stenmark KR, Orton EC, Reeves JT, et al. Vascular remodeling in neonatal pulmonary hypertension. Role of the smooth muscle cell. *Chest* 1988; 93: Suppl. 3, 1275–1335.

14 Cullinan C, Cox PN, Silver MM. Persistent pulmonary hypertension of the newborn due to alveolar capillary dysplasia. *Pediatr Pathol* 1992; 12: 499–514.

15 Heath D. Pulmonary hypertension in pulmonary parenchymal disease. *Cardiovasc Clin* 1972; 4: 79–96.

16 Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. *Am J Pathol* 1994; 144: 275–283.

17 Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; 43: Suppl. 12, 135–245.

18 Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. *N Engl J Med* 2003; 349: 1113–1122.

19 Boyer O, Saadoun D, Abriol J, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C mixed cryoglobulinemia vasculitis. *Blood* 2004; 103: 3428–3430.

20 Eddleston AL. Hepatitis C infection and autoimmunity. *J Hepatol* 1996; 24: Suppl. 2, 55–60.

21 Panasiuk A, Prokopowicz D, Zak J, Wysocka J. Peripheral blood T, B, and NK cells in relation to histological hepatitis activity and fibrosis stage in chronic hepatitis C. *Hepatogastroenterology* 2003; 50: 178–182.

22 Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr. Soluble and cellular markers of immune activation in patients with systemic sclerosis. *Clin Immunol Immunopathol* 1990; 56: 259–270.

23 Ingegnoli F, Trabattoni D, Saresella M, Fantini F, Clerici M. Distinct immune profiles characterize patients
with diffuse or limited systemic sclerosis. *Clin Immunol* 2003; 108: 21-28.

24 Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. *J Autoimmun* 2003; 21: 273–276.

25 Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. *Scand J Immunol* 2004; 59: 198–202.

26 Benveniste O, Cherin P, Maisonobe T, et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. *J Immunol* 2001; 167: 3521–3529.

27 Covas MI, Esquerda A, Garcia-Rico A, Mahy N. Peripheral blood T-lymphocyte subsets in autoimmune thyroid disease. *J Investig Allergol Clin Immunol* 1992; 2: 131–135.

28 Mandl T, Bredberg A, Jacobsson LT, Manthorpe R, Henriksson G. CD4 T-lymphocytopenia — a frequent finding in anti-SSA antibody seropositive patients with primary Sjogren's syndrome. *J Rheumatol* 2004; 31: 726–728.

29 Hooper MM, Niedermeyer J, Hoffmeyer F, Flemming P, Fabel H. Pulmonary hypertension after splenectomy? *Ann Intern Med* 1999; 130: 506–509.

30 Korniszewski L, Kurzyna M, Stolarski B, Torbicki A, Smerdel A, Ploski R. Fatal primary pulmonary hypertension in a 30-yr-old female with APECED syndrome. *Eur Respir J* 2003; 22: 709–711.

31 Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. *J Clin Pathol* 1991; 44: 1003–1006.

32 Yanai-Landau H, Amital H, Bar-Dayan Y, et al. Autoimmune aspects of primary pulmonary hypertension. *Pathobiology* 1995; 63: 71–75.

33 Karmochkine M, Cacoub P, Dorent R, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. *J Rheumatol* 1996; 23: 286–290.

34 Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. *J Rheumatol* 2002; 29: 282–287.

35 Couper JJ. Environmental triggers of type 1 diabetes. *J Paediatr Child Health* 2001; 37: 218–220.

36 Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. *J Clin Invest* 1996; 98: 785–792.

37 Wusirika R, Ferri C, Marin M, et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. *Am J Clin Pathol* 2003; 120: 596–606.

38 Negi VS, Tripathy NK, Misra R, Nityanand S. Anti-endothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. *J Rheumatol* 1998; 25: 462–466.

39 Vercellotti GM. Effects of viral activation of the vessel wall on inflammation and thrombosis. *Blood Coagul Fibrinolysis* 1998; 9: Suppl. 2, S3–S6.

40 Longo F, Saletta S, Lepore L, Pennesi M. Localized scleroderma after infection with Epstein-Barr virus. *Clin Exp Rheumatol* 1993; 11: 681–683.

41 Magro CM, Nuovo G, Ferri C, Crowson AN, Giuggioli D, Sebastiani M. Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. *J Cutan Pathol* 2004; 31: 43–50.

42 Ferri C, Longombardo G, Mugnaini P. Hepatitis E virus and systemic sclerosis. *QJM* 1998; 91: 375.

43 Ferri C, Zakrzewska K, Longombardo G, et al. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. *Clin Exp Rheumatol* 1999; 17: 718–720.

44 Harel L, Straussberg R, Rudich H, Cohen AH, Amir J. Raynaud’s phenomenon as a manifestation of parvovirus B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitic syndromes. *Clin Infect Dis* 2000; 30: 500–503.

45 Abu-Shakra M, Sukenis S, Buskila D. Systemic sclerosis: another rheumatic disease associated with hepatitis C virus infection. *Clin Rheumatol* 2000; 19: 378–380.

46 Hamamdzic D, Kasman LM, LeRoy EC. The role of infectious agents in the pathogenesis of systemic sclerosis. *Curr Opin Rheumatol* 2002; 14: 694–698.

47 Neidhart M, Kuchen S, Distler O, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. *Arthritis Rheum* 1999; 42: 389–392.

48 Vaughan JH, Shaw PX, Nguyen MD, et al. Evidence of activation of 2 herpesviruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins. *J Rheumatol* 2000; 27: 821–823.

49 Carapeto FJ, Winkelmann RK. Peripheral blood lymphocyte distribution in scleroderma. *Dermatologica* 1975; 151: 228–235.

50 Barnett AJ, Tait BD, Barnett MA, Toh BH. T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis). *Clin Immunol* 1989; 76: 24–29.

51 Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered B lymphocyte homeostasis in systemic sclerosis. *Clin Rheumatol* 2002; 21: 197–202.

52 Carreira PE. Pulmonary hypertension in autoimmune rheumatic diseases. *Autoimmun Rev* 2004; 3: 313–320.

53 Voelkel NF, Tudor RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. *Eur Respir J* 1995; 8: 2129–2138.

54 Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. *Am Rev Respir Dis* 1991; 144: 706–713.

55 Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. *Eur Respir J* 2003; 22: 358–363.

56 Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesis of the gonad after neonatal thymectomy in mice. *Science* 1969; 166: 753–755.

57 Penhale WJ, Farmer A, McKenna RP, Irvine WJ. Spontaneous thyroiditis in thymectomized and irradiated Wistar rats. *Clin Exp Immunol* 1973; 15: 225–236.

58 Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes
 damage after adoptive transfer. J Exp Med 1982; 156:1565–576.

59 Penhale WJ, Irvine WJ, Inglis JR, Farmer A. Thyroiditis in T cell-depleted rats: suppression of the autoallergic response by reconstitution with normal lymphoid cells. Clin Exp Immunol 1976; 25:6–16.

60 Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531–562.

61 Shih FF, Mandik-Nayak L, Wipke BT, Allen PM. Massive thymic deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T regulatory cells. J Exp Med 2004; 199:323–335.

62 Bystrzy RS, Aluvihare V, Welch KA, Kallikouri D, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001; 2:1126–1132.

63 Seo SJ, Fields ML, Buckler JL, et al. The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity 2002; 16:535–546.

64 Curotto de Lafaille MA, Murigalan S, et al. Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes. J Exp Med 2001; 194:1349–1359.

65 Tsubata T, Wu J, Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 1993; 364:645–648.

66 Lafaille JJ. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev 1998; 9:139–151.

67 Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15:427–438.

68 Renaudineau Y, Dugue C, Dueymes M, Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002; 1:365–372.

69 Sasaki N, Kurose A, Inoue H, Sawai T. [A possible role of anti-endothelial cell antibody in the sera of MCTD patients on pulmonary vascular damage relating to pulmonary hypertension]. Ryumachi 2002; 42:885–894.

70 Quismorio FP Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13:349–359.

71 Nakagawa N, Osanai S, Ide H, et al. Severe pulmonary hypertension associated with primary Sjogren’s syndrome. Intern Med 2003; 42:1248–1252.

72 Papo T, Piette JC, Legace E, et al. T lymphocyte subsets in primary antiphospholipid syndrome. J Rheumatol 1994; 21:2242–2245.

73 Ramos-Casals M, Cervera R, Lagrutta M, et al. Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Clin Infect Dis 2004; 38:1009–1016.

74 Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL. Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother 2003; 57:282–286.

75 Riboldi P, Gerosa M, Raschi E, Testoni C, Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003; 207:29–36.

76 Cheng HM, Hu C. Presence of IgG antiphospholipid autoantibody in nude mice. J Rheumatol 1995; 22:2006–2007.

77 Karulin AY, Hesse MD, Yip HC, Lehmann PV. Indirect IL-4 pathway in type 1 immunity. J Immunol 2002; 168:545–553.

78 Sherman MA. The role of STAT6 in mast cell IL-4 production. Immunol Rev 2001; 179:48–56.

79 Erb KJ, Ruger B, von Brevem N, Ryffel B, Schimpl A, Rivett K. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J Exp Med 1997; 185:329–339.

80 Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998; 28:2619–2629.

81 Ong CJ, Ip S, Teh SJ, et al. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999; 196:60–68.

82 Kodera T, McGaha TL, Phelps R, Paul WE, Bona CA. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 2002; 99:3800–3805.

83 Tucker A, McMurtry JF, Alexander AF, Reeves JT, Grover RF. Lung mast cell density and distribution in chronically hypoxic animals. J Appl Physiol 1977; 42:174–178.

84 Zhu YJ, Kradin R, Brandstetter RD, Staton G, Moss J, Hales CA. Hypoxic pulmonary hypertension in the mast cell-deficient mouse. J Appl Physiol 1983; 54:680–686.

85 Voelkel NF, Kruse HP. Disodium cromoglycat for symptomatic therapy of generalized mastocytosis. Int Med 1977; 4:325–330.

86 Castells MC. Mastocytosis: classification, diagnosis, and clinical presentation. Allergy Asthma Proc 2004; 25:33–36.

87 Miyata M, Sakuma F, Ito M, Ohira H, Sato Y, Kasukawa R. Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration. Int Arch Allergy Immunol 2000; 121:246–252.

88 Benoist C, Mathis D. Mast cells in autoimmune disease. Nature 2002; 420:875–878.

89 Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297:668–692.

90 Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:1628–631.

91 Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345:319–324.

92 Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14:627–644.

93 Hager-Theodorides AL, Outram SV, Shah DK, et al. Bone morphogenetic protein 2/4 signaling regulates early
thymocyte differentiation. J Immunol 2002; 169: 5496–5504.

94 Graf D, Nethisinghe S, Palmer DB, Fisher AG, Merkenschlager M. The developmentally regulated expression of twisted gastrulation reveals a role for bone morphogenetic proteins in the control of T cell development. J Exp Med 2002; 196: 163–171.

95 Tsai PT, Lee RA, Wu H. BMP4 acts upstream of FGF in modulating thymic stroma and regulating thymopoiesis. Blood 2003; 102: 3947–3953.

96 Ishisaki A, Yamato K, Hashimoto S, et al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem 1999; 274: 13637–13642.

97 Yamato K, Hashimoto S, Imamura T, et al. Activation of the p21(CIP1/WAF1) promoter by bone morphogenetic protein-2 in mouse B lineage cells. Oncogene 2001; 20: 4383–4392.

98 Nakayama N, Lee J, Chiu L. Vascular endothelial growth factor synergistically enhances bone morphogenetic protein-4-dependent lymphohematopoietic cell generation from embryonic stem cells in vitro. Blood 2000; 95: 2275–2283.

99 Tuder RM, Radisavljevic Z, Shroyer KR, Polak JM, Voelkel NF. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 1998; 158: 1999–2001.

100 Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1998; 114: Suppl. 3, 225S–230S.

101 Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22: 405–418.

102 D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343–349.

103 Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 56S–61S.

104 Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223–243.

105 MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453–459.

106 Sackner MA, Akgun N, Kimbel P, Lewis DH. The pathophysiology of scleroderma involving the heart and respiratory system. Ann Intern Med 1964; 60: 611–630.

107 Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977; 86: 394–399.

108 Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75: 65–74.

109 Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997; 27: 73–84.

110 Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273–277.